Recent VXRT News
- Vaxart Provides Business Update and Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:01:00 PM
- U.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices Climb • IH Market News • 03/14/2024 11:41:01 AM
- Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 02:23:54 PM
- Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:10:21 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:16:04 PM
- Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge • GlobeNewswire Inc. • 02/05/2024 01:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/02/2024 09:49:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 10:14:20 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/19/2024 09:30:58 PM
- Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate • GlobeNewswire Inc. • 01/19/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 10:18:45 PM
- Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management • GlobeNewswire Inc. • 01/16/2024 02:25:20 PM
- Vaxart, Inc. Announces Management Change • GlobeNewswire Inc. • 01/16/2024 02:22:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 02:19:43 PM
- Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers • GlobeNewswire Inc. • 12/21/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 08:16:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 08:11:19 PM
- Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/02/2023 08:01:22 PM
- Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2 • GlobeNewswire Inc. • 10/26/2023 12:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/23/2023 09:09:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 09:01:03 PM
HealthLynked Corp Announces Chris Hall as New Chief Technology Officer • HLYK • Mar 19, 2024 8:00 AM
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • ELAB • Mar 18, 2024 8:51 AM
Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • PEI • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM